Diabetes
Despite significant advancements in diabetes treatments, there remains a need for better insulin delivery and control. Arecor is focused on reducing patient burden, whilst improving outcomes.
AT278: A disruptor insulin - the only ultra-concentrated (500U/ml), ultra-rapid acting insulin
AT278 has the potential to drive and transform the use of AID delivery systems for patients.
With its best-in-class profile, it is the only ultra-concentrated (500U/mL) insulin suitable for AID pump use for high insulin users, and to catalyse a way for the next generation of miniaturised, longer wear pumps, making AID options available to more people with type 1 and type 2 diabetes.
AT278 is being jointly developed with Sequel Med Tech for use in its twiistTM AID system. twiistTM iiSureTM technology precisely measures each dose of insulin, making it an ideal AID system for highly concentrated (500U/mL) AT278.
The two companies are working together to prepare for the first FDA-approved combined insulin and AID system Phase 2 clinical trial.